Genentech sinks SHP2 pact, leaving Relay to race thinning field

17 Jul 2024
www.fiercebiotech.com
Phase 1License out/inPROTACs
Genentech tested GDC-1971 in four phase 1 clinical trials.
GenentechenentechGDC-1971ttled its SHP2 inhibitor pact, returning the rights to Relay Therapeutics after plowing more than $120 million into the alliance. The action is the latest in a series of terminations of SHP2 deals.
Roche21,Genentechh paid $75 millionSHP2 inhibitor pactSHP2ront to license Relay’s SHP2 inhibitor, aRelay Therapeuticsy called RLY-1971, migoprotafib or GDC-1971. The outlay reflected the company’s belief in the promise of pairing the molecule with its KRAS G12C inhibitor GDC-6036.
Several yGenentech$45 million in milestones later, GeneRelay haSHP2 inhibitorSHP2cided to terminate the R&D alliance withRLY-1971e,migoprotafibelayGDC-1971chance to pocket another $675 million in success-based paydays.KRAS G12C inhibitorKRAS G12CGDC-6036
The termination of the deal is part of a broader soGenentechf Big Pharma interest in SHP2. Sanofi began the exodus by axing its Revolution Medicines pact in 2022. AbbVie was the next to rethink its interest in SHP2, culling a deal with Jacobio in 2023, and Bristol Myers Squibb extended the trend by terminating its agreement with BridgeBio Pharma earlier this year. Amid that activity, Erasca axed its SHP2 program.
Some companies have kept the faith as the wider sector has soured on SHP2. Merck & CoSHP2teSanofito a SHP2 pact with Taiho and Astex in 2021 and is now enrolling pAbbVies in a phase 1 trial related to the targeSHP2ovartis is evaluating Jacobioinhibitor, TNOBristol Myers Squibbwith a KRAS G12C candidate in a phase 1/2 trial. A cluBridgeBio Pharmaompanies are still in the race too.ErascaErascaSHP2
Genentech tested GDC-1971 in four phase 1 clinical trials, three of wSHP2 aMerck & Co.y recruiting. The active trialsTaihoassesAstexthe SHP2 inhibitor in patients with advanced solid tumors including colorectal anNovartisall cell lung canSHP2 inhibitorSHP2 Depending oTNO155setting, Genentech has pKRAS G12C-1971 with Erbitux, Tagrisso, Tecentriq and its KRAS G12C inhibitor GDC-6036.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!